LATEST UPDATES » Christmas Edition: What's your 360o View?       » Hong Kong-Swiss joint medical researchers to fight Cancer       » New agreement launches collaboration between New Zealand and China in Medical Science       » Gait recorded by Smart Phone reveals Your Emotion       » What to expect in year 2050?       » International Mountain Day: Are we making a mountain out of a molehill?      
Pioneering drug discovery gets major funding to move to next stage
A pioneering drug development team at the University of Aberdeen has received a £1.5M funding boost to accelerate the progress of multiple novel drug leads to tackle cancer and diseases such as debilitating inflammatory conditions

Scottish Enterprise and Biotechnology and Biological Sciences Research Council have provided financial support for the innovative work which takes to the next level research first developed at the University a decade ago, that created novel therapies based on the immune system of one of the most ancient species on the planet - sharks.

The next-generation technologies now being developed - which will be spun out out of the University into a company later this year - uses small man-made proteins closely related to structures called Variable Novel Antigen Receptors (VNARS), found in the shark immune system. VNARs are the smallest molecule of this type identified so far in the animal kingdom.

The VNARs engineered by the team in the lab are the same size, and are being used to develop new drugs as well as to deliver - in a more tailored way - drugs into the body. Their small size will provide better penetration of solid cancer tumors and also make them capable of crossing into the brain. Their size, and less complicated structure, also potentially makes them much cheaper medicines than other related therapies. 

The team, comprising ex-industry professionals and leading academics, have successfully produced over 10 billion of these drug-like molecules. They say their VNAR drug library is the “equivalent to having access to 10,000 sharks without needing to keep a single animal in an aquarium”.  From this drug library they have already successfully gone “fishing” for new therapies to conditions such as cancer or inflammation. 

One of the team's VNARs can significantly extend the effective life of existing and new drugs in the body.  Typically drugs have to be taken every few hours. However, if joined to the new VNAR, their useful potency can be increased from hours to weeks. Other VNARs can specifically recognize, target and then destroy cancer cells.   By the end of this funding period the Aberdeen team aim to have produced drug candidates that not only have a long half-life but can also seek out and deliver deep into tumors powerful toxins that are tailor-made to kill cancer cells.  

The University's Professor Andy Porter and Dr. Caroline Barelle are heading up the research. They have already had success with the drug discovery company Haptogen Ltd - a University of Aberdeen spin-out that was bought by the US pharmaceutical company Wyeth Inc in 2007.

Professor Porter, Professor of Biotechnology and Director of the Scottish Biologics Facility, said: “We are excited and delighted with the support we have received from Scottish Enterprise and BBSRC for our research. These next-generation, targeted therapies show the potential to be more effective than current approaches, with less side-effects for patients and reduced costs of drug manufacture.” 

Dr. Barelle, Senior Research Fellow, added:  We have already received commercial interest in our progress to date and I hope to use my industry background to help turn our exciting drug leads into a new successful biotechnology company which we will spin-out from the University of Aberdeen.”

Professor Stephen Logan, Senior Vice-Principal for the University of Aberdeen, said: “This is ambitious and exciting research which will help build on Aberdeen's reputation as Scotland's commercial capital for drug discovery.”

Julia Brown, Director of Foresighting, Scottish Enterprise added: “Scottish Enterprise recognizes the international strength of the biologics research and commercialization capabilities of the University of Aberdeen and is pleased to be able to support this innovative project.  The technology involved has huge potential and the challenge now is to help translate this into a successful company, located in Scotland.”

Click here for the complete issue.

news Nanyang Technological University Smart Chip tells you how healthy your battery is
news Mechanobiology Institute, Singapore (MBI) and Cancer Science Institute of Singapore (CSI) at National University of Singapore
news The Future of Cities - A collaboration between Channel NewsAsia (Perspectives) and Newcastle University

Christiana Figueres on COP21 Paris and the World's Response to Climate Change click here.

APBN Editorial Calendar 2015
Trends and Predictions for 2015
Robotics in Healthcare
April & May:
Universal Health Coverage
Start-Up Biotech Companies
Preventative and Translational Medicine
ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development
Clear Air
December (Christmas Edition):
What's your 3600 view?
APBN Editorial Calendar 2016
Korea's Biotechnology Industry
Antibody Engineering in Japan
Life-Saving Opportunities: A Guide to Regenerative Medicine
Tobacco Smoking: The 'Real' Cost of One Cigarette
Medical Devices and Technology
Occupational Health
Water Technology
Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
Editorial calendar is subjected to changes. – Editor: Yuhui N Lin
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy